A compound of Formula (I) and pharmaceutically and/or veterinarily
acceptable derivatives thereof, wherein: R.sup.1, R.sup.2, R.sup.3 and
R.sup.20 are each independently H, Cl, Br, F, I, CF.sub.3, OCF.sub.3, Me
or Et; R.sup.4 is het or C.sub.3-7 cycloalkyl optionally substituted by
C.sub.1-4 alkyl, C.sub.1-4 alkoxy, alkoxyalkyl containing 2 to 4 carbon
atoms or --S--(C.sub.1-4 alkyl); a is 0 or 1; and het is a non-aromatic
4-, 5- or 6-membered heterocycle which contains at least one N, O or S
heteroatom, optionally fused to a 5- or 6-membered carbocyclic group or a
second 4-, 5- or 6-membered heterocycle which contains at least one N, O
or S heteroatom, wherein the het group is optionally substituted by at
least one substituent independently selected from C.sub.1-8alkyl,
C.sub.1-8alkoxy, OH, halo, CF.sub.3, OCF.sub.3, SCF.sub.3,
hydroxy-C.sub.1-6alkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl and
C.sub.1-4alkyl-S--C.sub.1-4alkyl; provided that at least one of R.sup.1,
R.sup.2 and R.sup.3 are other than H. The compounds of the invention
exhibit activity as both serotonin and noradrenaline re-uptake inhibitors
and therefore have utility in a variety of therapeutic areas, for example
urinary incontinence.